Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Neuromuscular Blockade Monitoring Methods in Gynecologic Oncology Surgery: NMTCuff (Vision Duo) Versus Standard Train-of-Four (Acceleromyography)

NCT07925463 is registered in ClinicalTrials.gov with Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07925463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Neuromuscular Blockade Monitoring Methods in Gynecologic Oncology Surgery: NMTCuff (Vision Duo) Versus Standard Train-of-Four (Acceleromyography)
Lead sponsor
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Phase
Observational
Overall status
Recruiting
Start date
September 1, 2026
Completion date
November 30, 2026
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gynecologic cancer, neuromuscular blockade, residual neuromuscular block

Arms

As registered; 1 arm.

  • Simultaneous Dual NMT Cohort Dual Neuromuscular Transmission Monitoring

    A single cohort of patients where each patient receives two different neuromuscular transmission (NMT) monitoring methods simultaneously on opposite arms during elective laparoscopic gynecologic oncology surgery.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Time to Neuromuscular Recovery (TOF Ratio >= 0.90) From the exact moment of Sugammadex administration up to endotracheal extubation (approximately 10 to 20 minutes).

    The time interval (measured in minutes) from the exact moment of the neuromuscular blockade reversal agent (Sugammadex 2 mg/kg) administration until the Train-of-Four (TOF) ratio reaches 90%. This recovery time will be tracked and recorded simultaneously for both the NMTCuff (Vision Duo) and the standard acceleromyography (AMG) devices using a digital stopwatch to evaluate the limits and correlation between the two monitoring methods.

Papers

PubMed papers this trial cites; 3 papers, results papers first, then newest first.

Source: PubMed, NCBI/NLM (public domain).

Lead sponsor's other trials

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, most recent start first.

Similar trials

Same condition (Delayed Emergence from Anesthesia) and phase, most recent start first.